Trends in oral corticosteroids use in severe asthma: a 14-year population-based study

[1] Hekking P-PW(2015)The prevalence of severe refractory asthma J Allergy Clin Immunol. 135 896-902

[2] Wener RR(2016)Utilization and costs of severe uncontrolled asthma in a managed-care setting J Allergy Clin Immunol Pract 4 e3-929

[3] Amelink M(2018)High prevalence of severe asthma in a large random population study J Allergy Clin Immunol. 141 2264-346

[4] Zwinderman AH(2001)Clinical predictors of health-related quality of life depend on asthma severity Am J Respir Crit Care Med 163 924-847

[5] Bouvy ML(2016)Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry Thorax 71 339-65

[6] Bel EH(2016)Dose-Response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma J Manag Care Spec Pharm 22 833-2141

[7] Zeiger RS(2017)Burden of systemic glucocorticoid-related complications in severe asthma Curr Med Res Opin 33 57-1207

[8] Schatz M(2017)Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma J Allergy Clin Immunol Pract 5 e9-2228

[9] Dalal AA(2016)Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 388 2128-918

[10] Qian L(2014)Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 1198-754

[1] Hekking P-PW(2015)The prevalence of severe refractory asthma J Allergy Clin Immunol. 135 896-902

[2] Wener RR(2016)Utilization and costs of severe uncontrolled asthma in a managed-care setting J Allergy Clin Immunol Pract 4 e3-929

[3] Amelink M(2018)High prevalence of severe asthma in a large random population study J Allergy Clin Immunol. 141 2264-346

[4] Zwinderman AH(2001)Clinical predictors of health-related quality of life depend on asthma severity Am J Respir Crit Care Med 163 924-847

[5] Bouvy ML(2016)Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry Thorax 71 339-65

[6] Bel EH(2016)Dose-Response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma J Manag Care Spec Pharm 22 833-2141

[7] Zeiger RS(2017)Burden of systemic glucocorticoid-related complications in severe asthma Curr Med Res Opin 33 57-1207

[8] Schatz M(2017)Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma J Allergy Clin Immunol Pract 5 e9-2228

[9] Dalal AA(2016)Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 388 2128-918

[10] Qian L(2014)Mepolizumab treatment in patients with severe eosinophilic asthma N Engl J Med 371 1198-754